The potential contradictory effects of BRCA1 on the two most common agents used to treat advanced ovarian cancer make it difficult to appreciate how alterations in BRCA1 mediate tumor response in patients treated with a combination of C + P. This evidence concerns the gene BRCA1 and ovarian carcinoma.